Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.

Silver Alkhafaji, Mark Jesus M Magbanua, Laura van t Veer, Karthik Giridhar, Matthew P. Goetz, Rita Mukhtar, Christos Vaklavas, Anthony D. Elias, Mei Wei, Gillian L. Hirst, Hope S. Rugo, Laura Ann Huppert, W. Fraser Fraser Symmans, Alexander D. Borowsky, Lamorna Brown Swigart, Natsuko Onishi, Douglas Yee, Nola Hylton, Laura Esserman, Jo Chien